baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Citi Call 200 PGR 20.06.2024/ DE000KJ0SX55 /

09/04/2024 09:26:16	Chg.-0.050	Bid14:58:53	Ask-	Underlying	Strike price	Expiration date	Option type
1.780EUR	-2.73%	- Bid Size: -	- Ask Size: -	Progressive Corporat...	200.00 -	20/06/2024	Call

GlobeNewswire 09/05 Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st ...

GlobeNewswire 09/05 Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate...

GlobeNewswire 08/05 Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Plan...

GlobeNewswire 07/05 MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-1...

GlobeNewswire 06/05 Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at th...

GlobeNewswire 04/05 The National Fire Sprinkler Association's Class of 2024: Honoring Fire Sprinkler Industry Greats

GlobeNewswire 02/05 PyroGenesis Announces 28-Day Lab Strength Tests Achieve Up to 99.56% Above Compressive Strength Targ...

GlobeNewswire 01/05 Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 A...

GlobeNewswire 01/05 Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 ...

GlobeNewswire 01/05 Opthea Announces Upcoming Presentations at the Retina World Congress 2024

GlobeNewswire 01/05 Atsena Therapeutics Announces Positive Clinical Data from the First Cohort of Phase I/II Trial Evalu...

GlobeNewswire 01/05 TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

GlobeNewswire 30/04 Progressive Announces Investor Relations Call

GlobeNewswire 25/04 Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Re...

GlobeNewswire 25/04 Opthea to Present at the OIS Retina Innovation Summit at ARVO

TeleTrader 25/04 Merck's Q1 sales rise by 9% to $15.8 billion

GlobeNewswire 24/04 Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society...

TeleTrader 23/04 Biden meets AOC amid divide on Israel policy

GlobeNewswire 22/04 BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Snap One Ho...

GlobeNewswire 22/04 Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients i...

GlobeNewswire 19/04 Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Scleros...

GlobeNewswire 18/04 Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with B...

GlobeNewswire 18/04 TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple ...

GlobeNewswire 18/04 Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting...

GlobeNewswire 18/04 TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the P...

Citi Call 200 PGR 20.06.2024/ DE000KJ0SX55 /

If you wish to receive reply to your feedback, please provide your email address.